Adjuvant immunotherapy.

James E Goodnight Jr, D. L. Morton

Research output: Contribution to journalArticle

Abstract

Because systemic spread occurs early in the growth of many malignancies, control of occult micrometastases must be an integral part of cancer treatment. For this reason, surgery and radiation therapy alone may fail to achieve a cure despite eradication of the primary tumor. Chemotherapy is potent and systemic in its effects but kills tumor cells by first-order kinetics so the last cancer cell may not be eliminated. An agent is needed that can selectively attack and destroy small numbers of tumor cells on a systemic basis without a significant increase in toxicity. Experimental observations indicate that immunotherapy could fill this role. Immunotherapy has been tested as an adjuvant to surgery, radiation therapy, and chemotherapy, and is clearly beneficial for selected cancer patients. There are many unresolved questions regarding the underlying mechanisms as well as the practical application of adjuvant immunotherapy, but the initial investigations indicate that it could play a vital part in the treatment of cancer. There is evidence that stimulation of host resistance can result in control of systemic micrometastases.

Original languageEnglish (US)
Pages (from-to)53-83
Number of pages31
JournalInternational advances in surgical oncology
Volume1
StatePublished - 1978
Externally publishedYes

Fingerprint

Immunotherapy
Neoplasms
Neoplasm Micrometastasis
Radiotherapy
Drug Therapy
Cell Count
Therapeutics
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Adjuvant immunotherapy. / Goodnight Jr, James E; Morton, D. L.

In: International advances in surgical oncology, Vol. 1, 1978, p. 53-83.

Research output: Contribution to journalArticle

@article{63831b3fbdab4cdabf8404348088a58f,
title = "Adjuvant immunotherapy.",
abstract = "Because systemic spread occurs early in the growth of many malignancies, control of occult micrometastases must be an integral part of cancer treatment. For this reason, surgery and radiation therapy alone may fail to achieve a cure despite eradication of the primary tumor. Chemotherapy is potent and systemic in its effects but kills tumor cells by first-order kinetics so the last cancer cell may not be eliminated. An agent is needed that can selectively attack and destroy small numbers of tumor cells on a systemic basis without a significant increase in toxicity. Experimental observations indicate that immunotherapy could fill this role. Immunotherapy has been tested as an adjuvant to surgery, radiation therapy, and chemotherapy, and is clearly beneficial for selected cancer patients. There are many unresolved questions regarding the underlying mechanisms as well as the practical application of adjuvant immunotherapy, but the initial investigations indicate that it could play a vital part in the treatment of cancer. There is evidence that stimulation of host resistance can result in control of systemic micrometastases.",
author = "{Goodnight Jr}, {James E} and Morton, {D. L.}",
year = "1978",
language = "English (US)",
volume = "1",
pages = "53--83",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Adjuvant immunotherapy.

AU - Goodnight Jr, James E

AU - Morton, D. L.

PY - 1978

Y1 - 1978

N2 - Because systemic spread occurs early in the growth of many malignancies, control of occult micrometastases must be an integral part of cancer treatment. For this reason, surgery and radiation therapy alone may fail to achieve a cure despite eradication of the primary tumor. Chemotherapy is potent and systemic in its effects but kills tumor cells by first-order kinetics so the last cancer cell may not be eliminated. An agent is needed that can selectively attack and destroy small numbers of tumor cells on a systemic basis without a significant increase in toxicity. Experimental observations indicate that immunotherapy could fill this role. Immunotherapy has been tested as an adjuvant to surgery, radiation therapy, and chemotherapy, and is clearly beneficial for selected cancer patients. There are many unresolved questions regarding the underlying mechanisms as well as the practical application of adjuvant immunotherapy, but the initial investigations indicate that it could play a vital part in the treatment of cancer. There is evidence that stimulation of host resistance can result in control of systemic micrometastases.

AB - Because systemic spread occurs early in the growth of many malignancies, control of occult micrometastases must be an integral part of cancer treatment. For this reason, surgery and radiation therapy alone may fail to achieve a cure despite eradication of the primary tumor. Chemotherapy is potent and systemic in its effects but kills tumor cells by first-order kinetics so the last cancer cell may not be eliminated. An agent is needed that can selectively attack and destroy small numbers of tumor cells on a systemic basis without a significant increase in toxicity. Experimental observations indicate that immunotherapy could fill this role. Immunotherapy has been tested as an adjuvant to surgery, radiation therapy, and chemotherapy, and is clearly beneficial for selected cancer patients. There are many unresolved questions regarding the underlying mechanisms as well as the practical application of adjuvant immunotherapy, but the initial investigations indicate that it could play a vital part in the treatment of cancer. There is evidence that stimulation of host resistance can result in control of systemic micrometastases.

UR - http://www.scopus.com/inward/record.url?scp=0018210833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018210833&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 53

EP - 83

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

ER -